Prolyl-isomerase pin1 impairs trastuzumab sensitivity by up-regulating fatty acid synthase expression

Anticancer Research

Volumn 34, Issue 3, 2014, Pages 1409-1416

  Yun, Hyo Jeong ^a   Kim, Jin Young ^a   Kim, Garam ^a   Choi, Hong Seok ^a  

^a Chosun University   (South Korea)

Author keywords

Chemoresistance; FAS; HER2; Pin1; Trastuzumab

Indexed keywords

FAS ANTIGEN; FATTY ACID SYNTHASE; JUGLONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEPTIDYLPROLYL ISOMERASE PIN1; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE; SREBF1 PROTEIN, HUMAN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; EMBRYO; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMORESISTANCE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FAS; GENE EXPRESSION REGULATION; GENETICS; HER2; METABOLISM; NUDE MOUSE; PATHOLOGY; PIN1; TUMOR CELL CULTURE; WESTERN BLOTTING;

CHEMORESISTANCE; FAS; HER2; PIN1; TRASTUZUMAB;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPIDERMAL GROWTH FACTOR; FATTY ACID SYNTHASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PEPTIDYLPROLYL ISOMERASE; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899697859     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
2. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nature reviews Molecular cell biology 2: 127-137, 2001.
3. Lan KH, Lu CH and Yu D: Mechanisms of trastuzumab resistance and their clinical implications. Annals of the New York Academy of Sciences 1059: 70-75, 2005.
4. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC and Yu D: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer cell 6: 117-127, 2004.
5. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ and Bernards R: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer cell 12: 395-402, 2007.
6. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J and Baselga J: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Journal of the National Cancer Institute 99: 628-638, 2007.
7. Weiss L, Hoffmann GE, Schreiber R, Andres H, Fuchs E, Korber E and Kolb HJ: Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biological chemistry Hoppe-Seyler 367: 905-912, 1986.
8. Alo PL, Visca P, Marci A, Mangoni A, Botti C and Di Tondo U: Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77: 474-482, 1996.
9. Menendez JA, Vellon L and Lupu R: Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Medical hypotheses 64: 997-1001, 2005.
10. Valabrega G, Montemurro F, Sarotto I, Petrelli A, Rubini P, Tacchetti C, Aglietta M, Comoglio PM and Giordano S: TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 24: 3002-3010, 2005.
11. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD and Pasternack GR: Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proceedings of the National Academy of Sciences of the United States of America 91: 6379-6383, 1994.
12. Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature reviews Cancer 7: 763-777, 2007.
13. Kuhajda FP: Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16: 202-208, 2000.
14. Takahashi K, Uchida C, Shin RW, Shimazaki K and Uchida T: Prolyl isomerase, Pin1: new findings of post-translational modifications and physiological substrates in cancer, asthma and Alzheimer's disease. Cellular and molecular life sciences: CMLS 65: 359-375, 2008.
15. Wulf G, Garg P, Liou YC, Iglehart D and Lu KP: Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. The EMBO journal 23: 3397-3407, 2004.
16. Lee NY, Choi HK, Shim JH, Kang KW, Dong Z and Choi HS: The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation. Carcinogenesis 30: 671-681, 2009.
17. Osborne CK, Shou J, Massarweh S and Schiff R: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 11: 865s-870s, 2005.
18. Namgoong GM, Khanal P, Cho HG, Lim SC, Oh YK, Kang BS, Shim JH, Yoo JC and Choi HS: The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. The Journal of biological chemistry 285: 23829-23841, 2010.
19. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Cuyas E, Lopez-Bonet E, Martin-Castillo B, Joven J and Menendez JA: The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2- positive breast cancer. Scientific reports 3: 2469, 2013.